Patent · US Active

Pazopanib formulation

US10596263B2 · kind B2 · utility

0Cited by

0References

6Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Gossett Augustus Campbell · Collegeville, US
Helen Richardson · Wrexham, GB
Peter Alexander Williams · Bar Harbor, US

Key dates

Filing date	Aug 22, 2018
Grant date	Mar 24, 2020
Priority date	—
Expiry date	Aug 22, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.